About
Daniel O'Connell, M.D., Ph.D., is an Associate on the Private Equity team. Before joining OrbiMed, Dr. O'Connell was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals. In this role, he headed projects developing small molecules to raise HDL-cholesterol, culminating with an FDA filing of a novel compound in 2010. He has authored articles in peer-reviewed journals describing the design and synthesis of novel enzyme inhibitors and the effects of niacin in animal models of dyslipidemia. Dr. O'Connell received his MD and his PhD in biochemistry at Tufts University School of Medicine. He holds SB degrees from MIT in both chemistry and mathematics.
Position in the VCSift Database
- • 7 investors at Arix Bioscience are tracked.
- • 145 investors hold the Investment Manager role in VCSift. Daniel O'Connell is one of them.
- • 10,621 investors are based in New York, New York, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- New York, US
Contact Information
Find more investors like Daniel
Search Investors